Vanderbilt University Medical Center: Chronic Complications From Immunotherapies More Prevalent and Persistent Than Previously Shown Among Melanoma Survivors
August 09, 2023
August 09, 2023
NASHVILLE, Tennessee, Aug. 9 -- Vanderbilt University Medical Center issued the following news:
By Tom Wilemon
Chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors, according to new research published Aug. 3 in JAMA Network Open.
Almost one-third (29.2%) of patients treated with either pembrolizumab or nivolumab experienced prolonged complications from the immunotherapies. The researche . . .
By Tom Wilemon
Chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors, according to new research published Aug. 3 in JAMA Network Open.
Almost one-third (29.2%) of patients treated with either pembrolizumab or nivolumab experienced prolonged complications from the immunotherapies. The researche . . .